PrEP treatment prevented HIV transmission in humanized mice

Jan 21, 2010

Systemic pre-exposure administration of antiretroviral drugs provides protection against intravenous and rectal transmission of HIV in mice with human immune systems, according to a new study published January 21, 2010 in the online journal PLoS ONE.

"These results provide evidence that a universal approach to prevent all forms of in all settings might be possible," said J. Victor Garcia-Martinez, Ph.D., professor in the department of medicine at the University of North Carolina at Chapel Hill School of Medicine and senior author of the study. "This could greatly facilitate the implementation of a single program capable of targeting virtually all groups of people at high risk of ."

According to data from the national Centers for Disease Control and Prevention, diagnoses increased by a staggering 15 percent between 2004 and 2007. Rectal exposure is the leading cause of HIV transmission among men who have sex with men, and since the beginning of the epidemic, more than 500,000 have been diagnosed with HIV in the United States alone and more than 300,000 have died.

These latest findings are welcome news after the recent announcements that an trial in Thailand showed only marginal success and a large international trial of a vaginal microbicide found no evidence that it reduces the risk of HIV infection.

The research, using pre-exposure prophylaxis (PrEP) with antiretrovirals, was conducted using a humanized mouse model developed by Garcia-Martinez and colleagues at the University of Texas Southwestern Medical Center. The animals are known as "BLT" mice, because they are transplanted with human , liver and thymus cells, which results in a fully functioning human .

"Although results from humanized mice cannot be extrapolated directly to humans, our data indicate that one intervention approach could potentially block multiple routes of HIV transmission in people," said the paper's lead author, Paul Denton, Ph.D., who is a research instructor in the department of medicine at the UNC School of Medicine.

The humanized mice were either control mice and received no drugs or were administered the commonly prescribed antiretroviral drug therapy Truvada and then exposed to HIV - either rectally or intravenously - at a level much higher than would occur in typical human exposure. None of the nine treated BLT mice that were exposed rectally showed any sign of the virus after exposure; they were completely protected. However, 12 of the 19 control BLT mice became HIV positive following rectal exposure.

Among humanized mice exposed intravenously, a transmission route which is more difficult to block, all six of the control BLT mice became infected, but seven of the eight treated BLT mice - 90 percent - were protected against the virus.

Garcia-Martinez's team previously demonstrated that PrEP is also highly effective against vaginal HIV transmission and with this study their research shows that PrEP can prevent HIV spread by the three modes that account for over 90 percent of all HIV infections worldwide.

Results of this study not only have important human clinical implications, but also could significantly improve drug studies. There are already PrEP trials in humans, but their continuation is threatened due in part to ethical concerns over administering drugs to healthy people with no hard evidence that they will work.

"Now the head of a clinical trial can take this research to a ministry of health or review board and say, 'Look, we have positive experimental evidence that if we do this right it has a chance to work,'" Denton said.

Mark Wainberg, Ph.D., who is professor of microbiology and virology at McGill University in Montréal and director of the McGill AIDS Centre, said, "This is outstanding work that helps to advance the field of HIV prevention science. This research provides excellent rationale for the continuation of PrEP clinical trials."

"It is painfully clear that treatment alone will not put a dent in the progression of the AIDS epidemic," said Garcia-Martinez, also an investigator in the UNC Center for AIDS Research. "There is a strong need for interventions like PrEP that could prevent new infections and slow the epidemic."

Explore further: Intimacy a strong motivator for PrEP HIV prevention

Provided by University of North Carolina

not rated yet

Related Stories

Targeted irradiation: A new weapon against HIV?

Nov 07, 2006

Antiretroviral therapy can keep HIV infection in check and delay and ameliorate the symptoms of HIV/AIDS. However, the drugs do not manage to eradicate the virus completely; individuals have to stay on the drugs permanently. ...

Recommended for you

Obese British man in court fight for surgery

Jul 11, 2011

A British man weighing 22 stone (139 kilograms, 306 pounds) launched a court appeal Monday against a decision to refuse him state-funded obesity surgery because he is not fat enough.

2008 crisis spurred rise in suicides in Europe

Jul 08, 2011

The financial crisis that began to hit Europe in mid-2008 reversed a steady, years-long fall in suicides among people of working age, according to a letter published on Friday by The Lancet.

New food labels dished up to keep Europe healthy

Jul 06, 2011

A groundbreaking deal on compulsory new food labels Wednesday is set to give Europeans clear information on the nutritional and energy content of products, as well as country of origin.

Overweight men have poorer sperm count

Jul 04, 2011

Overweight or obese men, like their female counterparts, have a lower chance of becoming a parent, according to a comparison of sperm quality presented at a European fertility meeting Monday.

User comments : 0